Check out our New Publishers' Select for Free Articles

Archives of Toxicology (v.79, #7)

New metabolites of di(2-ethylhexyl)phthalate (DEHP) in human urine and serum after single oral doses of deuterium-labelled DEHP by Holger M. Koch; Hermann M. Bolt; Ralf Preuss; Jürgen Angerer (pp. 367-376).

The metabolism of di(2-ethylhexyl)phthalate (DEHP) in humans was studied after three doses of 0.35 mg (4.7 μg/kg), 2.15 mg (28.7 μg/kg) and 48.5 mg (650 μg/kg) of D4-ring-labelled DEHP were administered orally to a male volunteer. Two new metabolites, mono(2-ethyl-5-carboxypentyl)phthalate (5cx-MEPP) and mono[2-(carboxymethyl)hexyl]phthalate (2cx-MMHP) were monitored for 44 h in urine and for 8 h in serum for the high-dose case, in addition to the three metabolites previously analysed: mono(2-ethyl-5-hydroxyhexyl)phthalate (5OH-MEHP), mono(2-ethyl-5-oxohexyl)phthalate (5oxo-MEHP) and mono(2-ethylhexyl)phthalate (MEHP). For the medium- and low-dose cases, 24 h urine samples were analysed. Up to 12 h after the dose, 5OH-MEHP was the major urinary metabolite, after 12 h it was 5cx-MEPP, and after 24 h it was 2cx-MMHP. The elimination half-lives of 5cx-MEHP and 2cx-MMHP were between 15 and 24 h. After 24 h 67.0% (range: 65.8–70.5%) of the DEHP dose was excreted in urine, comprising 5OH-MEHP (23.3%), 5cx-MEPP (18.5%), 5oxo-MEHP (15.0%), MEHP (5.9%) and 2cx-MMHP (4.2%). An additional 3.8% of the DEHP dose was excreted on the second day, comprising 2cx-MMHP (1.6%), 5cx-MEPP (1.2%), 5OH-MEHP (0.6%) and 5oxo-MEHP (0.4%). In total about 75% of the administered DEHP dose was excreted in urine after two days. Therefore, in contrast to previous studies, most of the orally administered DEHP is systemically absorbed and excreted in urine. No dose dependency in metabolism and excretion was observed. The secondary metabolites of DEHP are superior biomonitoring markers compared to any other parameters, such as MEHP in urine or blood. 5OH-MEHP and 5oxo-MEHP in urine reflect short-term and 5cx-MEHP and 2cx-MMHP long-term exposure. All secondary metabolites are unsusceptible to contamination. Furthermore, there are strong hints that the secondary oxidised DEHP metabolites—not DEHP or MEHP—are the ultimate developmental toxicants.

Keywords: Metabolism; Human; Urine; Serum; Di(2-ethylhexyl)phthalate (DEHP); Mono(2-ethyl-5-hydroxyhexyl)phthalate (5OH-MEHP); Mono(2-ethyl-5-oxo-hexyl)phthalate (5oxo-MEHP); Mono(2-ethyl-5-carboxypropyl)phthalate (5cx-MEPP); Mono[2-(carboxymethyl)hexyl]phthalate (2cx-MMHP); Mono(2-ethylhexyl)phthalate (MEHP)

hOGG1 SER326CYS genetic polymorphism in a Turkish population by Bensu Karahalil1; Neslihan Aygün Kocabaş (pp. 377-380).

Oxidative DNA damage, caused by either endogenous or exogenous sources of reactive oxygen species (ROS), has been linked to aging, chronic degenerative diseases, inflammatory diseases and cancers. 8-Hydroxydeoxyguanine (8-OHdG) is a major lesion produced by ROS. Among various types of DNA base modifications, 8-OHdG has been the most widely studied and is considered a key biomarker of oxidative DNA damage. Human 8-oxoguanine DNA glycosylase 1 (hOGG1) is a key component of the base excision repair (BER) pathway and catalyzes the removal of 8-OHdG. Ethnic and inter-individual differences in hOGG1 activity and several kinds of polymorphisms at the hOOG1 gene locus have been observed in the different populations studied so far. Since no information is available on the inter-individual variability of the hOGG1 genotype in the Turkish population, we genotyped 206 healthy, unrelated Turkish individuals. The allelic frequencies of the hOGG1 gene in the Turkish population were found to be 0.50, 0.41 and 0.09 (Ser/Ser, Ser/Cys and Cys/Cys, respectively). Our results are similar to those for Caucasians studied previously but are different from Asian populations. It seems that there is a growing need for extensive genotype studies with respect to the hOGG1 gene due to its importance to various types of cancer and to smoking habits.

Keywords: Ser326Cys polymorphismhOGG1 gene; Genetic polymorphism; Turkish population

Inducing coproporphyria in rat hepatocyte cultures using cyclic AMP and cyclic AMP-releasing agents by Francesco De Matteis; Carolyn Harvey (pp. 381-389).

Cyclic AMP (c-AMP), added on its own to rat hepatocyte cultures, caused a marked accumulation of coproporphyrin III. The results obtained by comparing the effect of c-AMP to that of exogenous 5-aminolevulinate (ALA), and from adding c-AMP and ALA together, indicated that the coproporphyrinogen III metabolism was blocked, even though no inhibition of the relevant enzyme, coproporphyrinogen oxidase, could be demonstrated. Preferential accumulation of coproporphyrin could also be produced in cultures of rat hepatocytes by agents that raise the cellular levels of cyclic AMP, such as glucagon. The effect of supplementing the culture medium with triiodothyronine (T3) on the response of rat hepatocytes to c-AMP was also investigated. T3, which is known to stimulate mitochondrial respiration, uncoupling O₂ consumption from ATP synthesis, produced a c-AMP-like effect when given on its own and potentiated the effect of c-AMP, with an apparent increase in the severity of the metabolic block. It is suggested that an oxidative mechanism may be activated in c-AMP and T₃-induced coproporphyria, preferentially involving the mitochondrial compartment, leading to oxidation of porphyrinogen intermediates of haem biosynthesis, especially coproporphyrinogen. Coproporphyin, the fully oxidized aromatic derivative produced, cannot be metabolized and will therefore accumulate.

Keywords: Porphyria; Rat hepatocytes; Cyclic AMP; Glucagon; Triiodothyronine

Evaluation of mechanisms inducing thyroid toxicity and the ability of the enhanced OECD Test Guideline 407 to detect these changes by G. Coelho-Palermo Cunha; B. van Ravenzwaay (pp. 390-405).

The OECD has developed an “enhanced Test Guideline 407” (TG 407) protocol for detecting endocrine effects during the course of a 28-day testing scheme. This protocol has gone through a validation process with (anti)estrogenic and (anti)androgenic compounds and substances that affect the thyroid (thyroxine and propylthiouracil). This review investigates whether a 28-day testing scheme would show up alterations in the thyroid-related parameters of the “enhanced TG 407” (T3, T4, TSH, thyroid weight and histopathology), irrespective of the mode of action. For each mode of action, a generally accepted reference chemical was selected and an in-depth literature survey was carried out, and the chemical was evaluated for treatment-related changes of thyroid-dependent parameters. The following model chemicals were selected: ion perchlorate, blockage of iodine uptake; propylthiouracil, inhibition of thyroid hormone synthesis; excess of iodine, blockage of thyroid hormone release; pyrazole, thyroid cytotoxicity; minocycline, thyroid pigmentation; amiodarone, inhibition of TSH synthesis; diethylstilbestrol, competition for thyroid hormone binding globulin; selenium-deficient diet, inhibition of thyroxine deiodination; FD&C Red No. 3, inhibition of peripheral 5′-deiodinase; cadmium, lipid peroxidation; phenobarbital, increase in thyroxine conjugation and biliary excretion; temelastine, thyroxine accumulation. Test data for treatments lasting approximately one month were available for most of these model chemicals, and these demonstrated the expected thyroid-related changes. Thus, it can be concluded that a 28-day testing scheme allows for the detection of thyroid-disrupting chemicals. The literature data also were evaluated according to whether preference can be given to any of the thyroid-related parameters (thyroid/pituitary hormones, thyroid weight and histopathology) with regard to dose-related sensitivities. Due to different study designs (such as treatment duration, application mode, dose selection and parameters used), no clear picture emerged. Therefore, consideration should be given to all of these parameters, which should also help to define the mode of action. Overall, this literature review provides support for the contention that the newly developed “enhanced TG 407” test protocol is well suited to the detection of chemicals that affect the thyroid gland.

Keywords: Thyroid toxicity; Rat; OECD Test Guideline 407; Mechanism

L-Carnitine halts apoptosis and myelosuppression induced by carboplatin in rat bone marrow cell cultures (BMC) by Adel R. A. Abd-Allah; Abdulhakeem A. Al-Majed; Abdulaziz A. Al-Yahya; Soliman I. Fouda; Othman A. Al-Shabana (pp. 406-413).

Carboplatin (CP), a second generation platinum compound, is effective against various types of cancers, producing less nephrotoxicity and ototoxicity but more myelotoxicity than cisplatinum. CP-myelosuppression is the rate-limiting step of its clinical use. Prevention of CP-myelosuppression is a major target in the field of chemotherapy. Therefore, the present study investigates the use of L-carnitine (LCR)—an antioxidant, cardioprotective, neuroprotective, and immunostimulant nontoxic natural compound—to protect against CP-induced myelosuppression. The viability of BMC was studied using a trypan blue exclusion technique following incubation with CP and/or LCR as a function of time and concentration. Apoptosis was tested for by detecting the amount of DNA fragmentation and the visualization of DNA ladders upon gel electrophoresis. Bone marrow progenitor cell function was examined by colony forming unit assay. Cellular contents of glutathione (GSH) and malondialdehyde (MDA) were also estimated. Results revealed that LC50 of CP is 4.7 mM and the highest safe concentration of LCR is 5 mM. Co-exposure of LCR+CP rescued BMC viability by 37% compared to the CP-treated cultures. The LCR halts CP-induced apoptosis and it significantly improves the function of the bone marrow progenitors by increasing the number of colony-forming units as a response to granulocyte/macrophage colony stimulating factors. Finally, LCR restores CP-induced GSH depletion and prevents MDA elevation in BMC. In summary, the results suggest that LCR is able to protect against CP-induced myelosuppression, which suggests its use as an adjuvant therapy. This finding merits further investigation into the mechanism(s) of such protection as well as its interaction with CP antitumor activity.

Keywords: MyelosuppressionL-carnitine; Carboplatin; Apoptosis; Antioxidant

Preliminary evaluation of an in utero-lactation assay using 6-n-propyl-2-thiouracil by Shuji Noda; Takako Muroi; Saori Takakura; Satoko Sakamoto; Mineo Takatsuki; Kanji Yamasaki; Susumu Tateyama; Ryoji Yamaguchi (pp. 414-421).

In this preliminary study, the potential of an in utero-lactation assay to detect thyroid effectors was evaluated by treating three dams/group with 6-n-propyl-2-thiouracil (PTU), a known thyroid antagonist, by oral gavage at doses of 0, 0.0032, 0.016, 0.08 and 0.4 mg/kg/day during fetal organogenesis and lactation. Hearing disturbances and an elevated relative thyroid weight were observed in offspring of both sexes in the 0.4 mg/kg/day group. The Biel-type water T-maze test showed an increase in the number of errors made by females in the 0.4 mg/kg/day group. Histopathologically, flattening of follicular epithelium, a decrease in resorptive colloid droplets, degeneration of follicular epithelium, and hyperplasia of follicular epithelium were observed in males belonging to the 0.4 mg/kg/day group. Histopathological abnormalities were also observed in some offspring belonging to the 0.08 mg/kg/day group. In the dams, hypertrophy of the follicular epithelium of the thyroid was observed in the 0.4 mg/kg/day group. Although we could not explain the mechanism for the difference in the effects seen in the offspring and the dams, the effect of PTU in utero through lactational exposure is apparently different from that resulting from exposure in homeostatically mature rats. Most reports studying PTU have involved administration in water or in food, and reports on the oral gavage of PTU during the fetal organogenesis and lactation period are very rare. This assumes that dosages >0.4 mg/kg/day would also produce clear anti-thyroid effects by oral gavage and, possibly, emphasizes that dosages <0.4 mg/kg/day did not have a noticeable effect. Based on the present results, a study to determine the reproducibility of the data in a much larger number of dams will be performed to confirm the findings in the present study, and to evaluate other endpoints, such as hormonal evaluation of dams and their offspring, sexual developmental landmarks, and fertility of the offspring.

Keywords: Rat; In utero-lactation assay; PTU; Oral gavage; Histopathological effects on thyroid

Micronucleus test in mussels Perna perna fed with the toxic dinoflagellate Prorocentrum lima by CR Carvalho Pinto-Silva; E. E. Creppy; W. G. Matias (pp. 422-426).

Micronucleus (MN) and other nuclear abnormalities have been measured in the hemocytes of mussels Perna perna to verify whether feeding mussels with different concentrations of Prorocentrum lima results in accumulation of levels of okadaic acid (OA) capable of inducing genotoxic effects at the chromosome level, as evidenced by micronuclei and nuclear abnormalities. Four groups of 12 mussels housed individually in aquaria containing filtered seawater were fed with different concentrations of P. lima. Another group collected directly from the production area served as outdoor control. A significantly higher frequency of MN and nuclear lesions was observed in hemocytes from the groups fed P. lima.

Keywords: Prorocentrum limaMarine toxins; Mussel; MicronucleusPerna pernaDSP toxins

Sections

Personal tools

Archives of Toxicology (v.79, #7)

Sections

Personal tools

Local resources

Archives of Toxicology (v.79, #7)